Wednesday, November 30, 2016

Axtria® Inc. Announces a Strategic Agreement to Improve Productivity & Effectiveness Through Incentives and Bonuses for All Global Commercial Teams on the Cloud-Based Axtria SalesIQ™ Platform

BERKELEY HEIGHTS, N.J. - Wednesday, November 30th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Axtria, a global big data analytics company, is pleased to announce a strategic agreement with Boehringer Ingelheim (a top 20 pharmaceutical manufacturer) to provide end-to-end Incentive Compensation services to its global commercial teams. As part of the agreement, over 12,000 users across Boehringer Ingelheim’s global markets will be deployed on Axtria’s SalesIQ. There are already 3,500 users in the US and Japan live on the platform today.

Previously, all bonus and incentive processes at Boehringer Ingelheim were localized within each business unit and region. With a focus on driving field force effectiveness, Boehringer Ingelheim aims to standardize on a modern, enterprise-grade platform that align compensation strategies and implements best practices globally.

“Axtria proved that they not only have a strong platform and experience to deploy in an agile way a state of the art bonuses and incentives platform but also proved they have a strong global experience on how to bring to the next level Customer Facing Roles motivation through bonuses and incentives therefore impacting their productivity and effectiveness.” said Dave Arnold, Head of Customer Engagement Excellence at Boehringer Ingelheim.

Axtria SalesIQ is an integrated, cloud based sales planning and operations platform covering Territory Alignment, Call Planning, Incentive Compensation and Field Reporting. It is built on the platform and integrates natively with Veeva CRM.

As part of the transformation, Boehringer Ingelheim expects Axtria SalesIQ to deliver:

    A scalable, enterprise-grade incentive compensation platform
    A global solution that drives standardization across markets
    Flexibility to work with localized data, currencies, credits and languages
    Agility to adapt and grow with evolving business needs
    A reduction in administration errors, often caused by spreadsheets and manual processes
    Improvements in controls and transparency across business processes

“We are excited to be partnering with Boehringer Ingelheim on this strategic initiative” said Jassi Chadha, Founder and CEO of Axtria. “This is a testament to the impact that our cloud solutions have on Commercial Operations processes. We look forward to delivering on the vision, improving field force effectiveness and incentivizing the right behaviors across the globe.”

To learn more about Axtria and their cloud solutions, please visit

About Boehringer Ingelheim

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

About Axtria

Axtria is a global big data analytics company. We help leaders across the Life Sciences and Financial Services industries make better data-driven decisions.

We help to optimize business strategy by delivering cutting edge analytics from the broadest set of data sources, combined with deep technical and domain expertise. We enable commercial excellence by eliminating spreadsheets and delivering analytical guidance to the field through Axtria SalesIQ, our cloud based sales planning and operations platform. We are leaders in managing data using the latest cloud information management and big data technologies.

We have more than 800 employees worldwide, we are growing rapidly, and we are proud to count 8 of the top 10 global Life Sciences companies and 2 of the Top 5 global banks as our customers.


Axtria and Axtria SalesIQ are registered trademarks of Axtria. Other names may be trademarks of their respective owners.



Andrew Keleher, +1-877-929-8742

Senior Director of Marketing


Takeda to Invest More Than 100 Million Euros in Dengue Vaccine Manufacturing Plant in Germany

KONSTANZ, Germany & OSAKA, Japan - Wednesday, November 30th 2016 [ME NewsWire]

    Decision follows the successful initiation of TIDES, the global Phase 3 clinical trial to evaluate the efficacy of a two-dose schedule of Takeda’s dengue vaccine candidate
    40% of the world’s population lives under the threat of the dengue virus
    Manufacturing plant is major step towards meeting important unmet needs in dengue prevention

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502) (“Takeda”) today announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany. This represents a major step by Takeda toward meeting important unmet needs in dengue prevention. According to the World Health Organization (WHO), dengue is the fastest spreading mosquito-borne viral disease. Forty percent of the world’s population lives under the threat of the dengue virus, which causes an estimated 390 million infections and more than 20,000 deaths each year around the world in people of all ages.

“This manufacturing plant investment reinforces Takeda’s strong support for our global vaccine strategy in general, and dengue in particular. The new plant will provide millions of people with access to a medicine that addresses a huge unmet medical need. It underlines our commitment to improve the lives of people worldwide,” says Dr. Thomas Wozniewski, Global Manufacturing & Supply Officer at Takeda.

“Our colleagues in Singen have vast experience in lyophilisation technology, which is key for the manufacturing process of Takeda’s dengue vaccine finished product,” notes Thomas Wozniewski. Initial construction activities will start immediately, and the facility should be ready for production in 2019.

On September 7, 2016 Takeda vaccinated the first subject in the Tetravalent Immunization against Dengue Efficacy Study (TIDES). TIDES is now enrolling approximately 20,000 healthy children between the ages of four and 16 years living in dengue-endemic countries in Latin America and Asia. The study is a Phase 3 double-blind, randomized, placebo-controlled trial of Takeda’s live-attenuated tetravalent dengue vaccine candidate. The study is evaluating the efficacy of the vaccine candidate to protect subjects against symptomatic dengue fever caused by any of the four dengue virus serotypes, regardless of age and whether the individual has previously been exposed to the virus. The study is also evaluating vaccine safety and immunogenicity, with two doses of the vaccine candidate or placebo administered 90 days apart.

Dr. Rajeev Venkayya, President of Takeda Vaccines, adds “This dengue vaccine production facility is another strong indication of Takeda’s long-term commitment to vaccines. The progress of the dengue TIDES clinical trial, our partnership with the Bill & Melinda Gates Foundation to eradicate polio, the recent initiation of the world’s first field efficacy trial for a norovirus vaccine, and our work with the U.S. Government to develop a Zika vaccine, together demonstrate how Takeda is dedicated to developing and providing vaccines to protect people in need wherever they are.”

About the Dengue Vaccine Candidate (TAK-003)
Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus (DENV-2), which provides the genetic ‘backbone’ for all four vaccine viruses. Takeda’s dengue vaccine is being developed to support the protection of populations and individuals at risk for dengue across geographies whether or not they have had previous exposure to dengue virus, including: children and adults, travelers and those living in endemic areas.

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit
Additional information about Takeda is available through its corporate website,


Media Contacts:

Takeda Pharmaceutical Company Limited

Tsuyoshi Tada, +81 (0) 3-3278-2417


Patient Safety Movement Foundation Names Dr. Jannicke Mellin-Olsen to Its Board of Directors

Dr. Mellin-Olsen, the Driving Force for the Landmark Helsinki Declaration on Patient Safety in Anaesthesiology, Joins the Patient Safety Movement as First International Board Member

IRVINE, Calif. - Tuesday, November 29th 2016 [ME NewsWire]

(BUSINESS WIRE)-- The Patient Safety Movement Foundation (PSMF) has named long-time patient safety advocate Jannicke Mellin-Olsen, MD, DPH, to its Board of Directors. In addition to her full-time clinical post in Bærum Hospital in Oslo, Norway, Dr. Mellin-Olsen serves as Secretary of the European Society of Anesthesiology and President-Elect of the World Federation of Societies of Anaesthesiologists.

“We feel very fortunate to have Dr. Mellin-Olsen join our board,” said Joe Kiani, Founder and Chairman of the Patient Safety Movement Foundation. “For over 25 years, Dr. Mellin-Olsen has been extremely active internationally in promoting safe anesthesiology practices, dedicating her life to saving patients from avoidable harm and death. With the help of respected and committed leaders like Dr. Mellin-Olsen, we hope to one day eliminate all preventable patient deaths on every continent.”

Dr. Mellin-Olsen began working on patient safety initiatives during her residence training at Trondheim University Hospital, Norway, where she earned her specialty in 1992. She is currently full-time practicing clinical anaesthesiologist in Bærum Hospital, Norway. She has served in the UN Peace Keeping Forces in Lebanon and for the Red Cross in Pakistan and Serbia, and for 10 years, she was the medical director for Europe, Middle East, and Africa for MedAire, Inc., which provides remote medical services to patients in the air and at sea. While serving on the European Board of Anaesthesiology, she chaired the Patient Safety and Quality Committee, and later, during her presidency, she was the driving force for the landmark Helsinki Declaration on Patient Safety in Anaesthesiology, which launched in 2010. Dr. Mellin-Olsen also serves as the Foundation’s Regional Network Chair, spreading the mission of the Foundation to stakeholders across Europe. She is the Secretary of the European Society of Anaesthesiology and the President-Elect of the World Federation of Societies of Anaesthesiologists.

“I’m honored to serve on the Board of Directors of the Patient Safety Movement Foundation, a natural extension of my patient safety advocacy work around the world,” said Dr. Mellin-Olsen. “When a patient entrusts the health system with his or her life, it is our sworn duty as clinicians to protect that patient from any preventable harm. I look forward to helping expedite their efforts internationally and involve more stakeholders across the globe in their mission to eliminate preventable deaths in hospitals.”

The Patient Safety Movement Foundation board members include; Dr. Steven Barker, Professor Emeritus of Anesthesiology, University of Arizona, and CSO of Masimo; Robin Betts, MBA-HM, RN, Assistant Vice President of Quality of Patient Safety; Alicia Cole, Executive Director of the Alliance for Safety Awareness for Patients; Omar Ishrak, Chairman and CEO of Medtronic plc; David Mayer, MD, Vice President of Quality and Safety for MedStar Health; Jim Messina, CEO of The Messina Group; Charlie Miceli, Vice President of Information Systems & Supply Chain for Fletcher Allen Health Care; Tamra E. Minnier, RN, MSN, FACHE, Chief Quality Officer, University of Pittsburgh Medical Center; Steven Moreau, President & Chief Executive Officer of St. Joseph Hospital; and Michael A. E. Ramsay, MD, FRCA, Chairman of the Department of Anesthesiology, Baylor University Medical Center, and President of the Baylor Research Institute.

About the Patient Safety Movement Foundation

More than 200,000 people die every year in U.S. hospitals in ways that could have been prevented. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare, to reduce that number of preventable deaths to 0 by 2020 (0x2020). Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems and solutions of patient safety. The Foundation also convenes Patient Safety, Science and Technology summits. The first annual Summit was held in January 2013 and brought together some of our nation’s best minds for thought-provoking discussions and new ideas to challenge the status quo. By presenting specific, high-impact recipes to meet patient safety challenges, encouraging medical technology companies to share the data for whom their products are purchased, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Foundation is working toward zero preventable deaths by 2020. Visit

@0x2020 #patientsafety #0x2020


Patient Safety Movement Foundation

Irene Paigah, 858-859-7001


Nordson EFD Explains How to Choose Dispensing Tips in New Series of Educational Videos

Videos help viewers learn quickly and easily how to select the right dispensing tip for a particular fluid and application

EAST PROVIDENCE, R.I. - Tuesday, November 29th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Nordson EFD, a Nordson company (NASDAQ: NDSN) and the world’s leading manufacturer of precision fluid dispensing systems, introduces a new Better Dispensing™ How-To Video series. These first three short but highly instructional videos, hosted by EFD Application Specialist Tom Muccino, provide best practices when selecting a dispense tip.

“The dispensing tip is one of the most important parts of the dispensing system,” said Muccino in the first overview how-to video. “So you don’t want to choose just any tip that works. You want to choose the best tip for the application.”

Nordson EFD manufactures hundreds of different dispensing tips with varying lengths, gauges, angles, and other features designed to optimize dispensing repeatability and accuracy for each fluid type and application.

    The first video provides a brief overview of the different types of dispense tips available and types of fluids they’re best used with.
    The second video outlines the most optimal dispense tips to use with medium-to-thick viscosity fluids to achieve benefits such as increased productivity.
    The third video provides useful information about dispense tips that prevent wicking and dripping when dispensing low-viscosity fluids. It also outlines specialty tips that prevent premature curing of cyanoacrylates in the cannula.

These three Better Dispensing How-To Videos are the first in a series of educational videos from Nordson EFD that will provide best practices to help manufacturers improve dispensing processes to achieve greater throughput while reducing rejects, rework, and fluid waste. Visit to watch future installments.

For more information, email Nordson EFD at, or call +1 401.431.7000 or 800.556.3484.

About Nordson EFD

Nordson EFD designs and manufactures precision fluid dispensing systems for benchtop assembly processes and automated assembly lines. By enabling manufacturers to apply the same amount of adhesive, lubricant or other assembly fluid to every part, every time, EFD dispensing systems are helping companies in a wide variety of industries increase throughput, improve quality, and lower their production costs. Other fluid management capabilities include high-quality syringe barrels and cartridges for packaging one- and two-component materials, along with a wide variety of fittings, couplers and connectors for controlling fluid flow in medical, biopharmaceutical and industrial environments. The company is also a leading formulator of specialty solder pastes for dispensing and printing applications in the electronics industry.

About Nordson Corporation

Nordson engineers, manufactures, and markets differentiated products and systems used for dispensing and processing adhesives, coatings, polymers, sealants and biomaterials; and for managing fluids, testing and inspecting for quality, treating surfaces and curing. These products are supported with extensive application expertise and direct global sales and service. We serve a wide variety of consumer non-durable, consumer durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, building and construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in more than 30 countries. Visit Nordson on the web at, or

Photos/Multimedia Gallery Available:


Nordson EFD

Natalie Tomasso +1-401-431-7173 (USA)

Marketing Communications Specialist


Ideagraphics, Inc.

Gaylen Whittier (agency), +1-401-438-9727


Nordson EFD


Natalie Tomasso, +1-401-431-7173


+44 (0) 1582 666334


+86 (21) 3866 9006



+81 (03) 5762 2760


+65 6796 9522



+91 80 4021 3600


Tuesday, November 29, 2016

AURAK Launches Innovation Week Program

Ras Al Khaimah, United Arab Emirates - Thursday, November 24th 2016 [ME NewsWire]

The American University of Ras Al Khaimah (AURAK) has launched its comprehensive program for the second annual Innovation Week initiative, as decreed by His Highness Sheikh Mohammed bin Rashid Al Maktoum, UAE Vice President and Prime Minister and Ruler of Dubai.

The university held an innovation competition for students earlier this month, giving them the opportunity to put forward their projects, the best of which have been selected for display at this week’s innovation exhibition at Ras Al Khaimah Exhibition Center.

The winning project was a mobile phone application, available on iPhone and Android, which utilizes QR code technology which allows users to exchange jigsaw pieces in order to complete a picture. With the UAE National Day approaching, the first jigsaw that creators, Aisha El Allam and Maryam Abdulla, coded into the application was a picture of the seven sheikhs of the seven emirates.

Speaking of their inspiration for creating the app, which was under the supervision of Dr. Said Elnaffar, Aisha commented, “We all love and appreciate the peace and prosperity that the UAE offers us, so we created this app with the intention of allowing people to connect and socialize based on their mutual love for this country. The app was also designed so that people have to physically meet and talk to each other, rather than ‘socializing’ in cyberspace.”

The second place project, overseen by mentor Dr. Abdul Gafoor Puthiyaveetil, was produced by two junior biotechnology students: Najath Abdulkareem and Nada Anwar. With the rapidly increasing population of the planet, they reasoned, food production is more important than ever. Their adapted idea, vertical farming, deals with growing food indoors on a tiered platform using a combination of sunlight and LED lights. The layout maximizes efficiency through reusing water and saving space. The pair of students have successfully grown the likes of basil, parsley, rosemary and mint within their own homes.

A number of other projects were also on display, including a conceptual design for a smartphone screen which can produce text in braille to assist the visually impaired, as well as an innovative teaching method based on sensory stimulation which has had positive results in the field of special needs education. The projects were viewed by the crown prince of Ras Al Khaimah, H. H. Sheikh Mohammad bin Saud Al Qassimi, who congratulated the students on their inventiveness.

Commenting at the event, AURAK president, Professor Hassan Hamdan Al Alkim, commented, “This is a great opportunity to demonstrate to the community the extent of the innovation and research going on at the university. We are producing knowledge in all fields and we have students, who are aided by top-class professors, who are being given the opportunity to actively participate in this process.”


Eóin Brown

Marketing and Public Relations Department, +971 7 2210900 Ext: 1325


AHF’s Campaign to Fight HIV Amongst Young Women and Girls (GIRLS ACT) Heads to South Africa, Nigeria & Kenya

KAMPALA, Uganda - Friday, November 25th 2016 [ME NewsWire]

(BUSINESS WIRE)-- The AIDS Healthcare Foundation, Africa Bureau will launch its campaign to fight HIV amongst young women and girls aged 15-24 in South Africa and Nigeria on the 25th and in Kenya on the 29th of November. This is coming after a successful launch of the same campaign in Uganda about 3 weeks ago.

The campaign dubbed Girls’ ACT (Awareness Campaign Tour) is largely informed by the compelling fact that young women and adolescent girls account for one in five new HIV infections in Africa and are almost three times more likely than their male counterparts to be living with HIV in sub-Saharan Africa. This is highlighted in the 2013 report of the Joint United Nations Program on HIV/AIDS (UNAIDS), which states that almost 60% of all new HIV infections among young people aged 15–24 occurred among adolescent girls and young women and 80% of them live in sub-Saharan Africa. “These statistics spotlights the disproportion that young women and girls face in the HIV/AIDS epidemic and begs for more strategic and relatable approaches," said Dr. Adetayo Towolawi, Country Program Manager, AHF Nigeria. “It is therefore imperative that we reach out to these young women and girls in an aggressive manner, leaving no stone unturned and no one behind.”

Girls’ ACT, is a multi-institutional drive that primarily aims to; a) scale up HIV/AIDS prevention services in order to curb new HIV infections amongst this population sub-group, and b) ensure that young people living with HIV are enrolled and retained in HIV care for improved health outcomes. “To achieve this, AHF is working together with partners from government, civil society and business, to offer a range of health services including HIV and TB tests, Sexual reproductive health, menstrual health and self-esteem, counseling on gender-based violence, and pro-bono legal services for victims of violation or abuse,” added Hilary Thulare, Country Program Director, AHF South Africa “Together we can empower our communities to ACT against HIV and sexual violence and promote positive living with dignity amongst young women and adolescent girls.”

“Our safe space programs and interactions with young people in Kenya, has given us a great opportunity to understand the needs of young women and girls better, and insights on how best to support them,” said Dr. Wamae Maranga, Country Director, AHF Kenya. “Majority of the girls do not visit health facilities for various reasons, and those living with HIV continue to struggle with self-esteem issues and stigma, which negatively impact their health. Therefore, if we want to get different results, we must do things differently and that is where an out-of-the-box initiative such as the GIRLS ACT comes to bare.”

The GIRLS ACT campaign, which takes the form of a concert-like caravan, aims to bring services closer to communities, targeting young women and adolescent girls from all walks of life, different socioeconomic groupings and dwellings. However, their male counterparts and the general community as key gatekeepers for young girls’ protection will also benefit by accessing HIV/AIDS related information & services as well as other connect services.

“Young women and girls are a major focus for us at AHF right now. We want to see them live healthy lives and make informed decisions about their health, so we can break the cycle of new infections,” said Terri Ford, Chief of Global advocacy and Policy. “We cannot afford to be complacent about this and to see how the GIRLS ACT has gained so much buy-in and huge followership, is proof that we need young people at the heart of these interventions. We have to keep them alive and well”!

Speaking on the success of the campaign in Uganda, AHF Africa Bureau Chief, Dr. Penninah Iutung shared thus “At the Uganda launch, Girls ACT was well received by stakeholders and partners alike; who have committed to working with us on this project as we move to more districts.” Beyond the strengthened partnerships, the most significant and remarkable outcome from the launch was witnessing young women and girls who had fallen out of treatment, get re-enrolled. That was an absolute indication that we are on the right track”. “We will continue to work closely with young people across our country programs to see what works best for them, in order to ensure they have access to the much needed care and information,” she enthused.



Kemi Gbadamosi

Senior Manager, PR & Communications, Africa Bureau


Alice Kayongo

Regional Policy & Advocacy Manager, E/W Africa


Larissa Klazinga

Regional Policy & Advocacy Manager, Southern Africa


TRIGO Group and PSA Group Partnership

PARIS - Tuesday, November 29th 2016 [ME NewsWire]

(BUSINESS WIRE)-- TRIGO has been awarded a strategic contract by PSA Group to provide extensive quality services in France for the upcoming years.

The cooperation between TRIGO and PSA Group started two decades ago and has been developed in many locations worldwide where PSA Group operates. As a result of a proposal opportunity launched in France in 2016, TRIGO became the trusted quality service provider at 13 French PSA manufacturing sites.

TRIGO’s innovative quality solutions are significantly facilitating the automotive manufacturer’s operations and improving its competitiveness by covering the complete OEM manufacturing process and offering a comprehensive quality service portfolio, including Containment and Sorting actions, Quality Firewall, Vehicle Launch Support, In-process and Final Vehicle Inspection, Software Update, Initial Sample Management, Non-conformity Analysis, Supplier Training and Audit, and more.

Additionally, TRIGO’s leading position in providing technical OEM services such as Mechanical Rework, Electronic Diagnosis, Electrical Rework, Saddlery, Painting, Bare Sheet and Painted Car Body Repair benefited its position to be chosen as a strategic quality partner by the French manufacturer.

Furthermore, the TRIGO Academy offering extensive Quality Trainings and premium Technical Expertise in Inspection and Technical Repair to OEM and Tier-1 customers as well as TRIGO internal associates, has also contributed to set up a successful cooperation with PSA Group for the upcoming years.

"We are very proud to strengthen further our partnership with PSA Group and to become the trusted quality services provider in France. This is a clear market recognition of TRIGO’s successful strategic development and unique market positioning in France and worldwide. Our competitive, extensive and technical quality service portfolio is a key asset for the automotive OEMs to successfully achieve the challenging quality targets required in this industry. This is also a strong reward to our operational teams who deliver a best-in-class daily service to PSA Group while sharing the values of operational excellence and customer satisfaction,” says Julien Laforets, Managing Director of TRIGO France.


Founded in 1997, TRIGO is a multinational company providing operational Quality Management solutions for the manufacturing sector, especially in the transportation industries. With a team of more than 7000 professionals present in 20+ countries across 4 continents, TRIGO offers a comprehensive portfolio of Quality Inspection, Engineering, and Management Services all along the supply chain.

For more information, please visit


With sales and revenue of €54 billion in 2015, the PSA Group designs unique automotive experiences and delivers mobility solutions that provide freedom and enjoyment to customers around the world. The Group leverages the models from its three brands, Peugeot, Citroën and DS, as well as a wide array of mobility services, such as Free2Move, to meet the evolving needs and expectations of automobile users. PSA is the European leader in terms of CO2 emissions, with average emissions of 104.4 grams of CO2 per kilometer in 2015, and an early innovator in the field of autonomous and connected cars, with 1.8 million such vehicles worldwide. It is also involved in financing activities through Banque PSA Finance and in automotive equipment via Faurecia.

For more information, please visit



Mercédesz Trum

Group Marketing Manager, +36 30 485 83 53


Global Game Exhibition "G-STAR 2016" Breaks New Attendance Record

BUSAN, South Korea - Friday, November 25th 2016 [ME NewsWire]

4 days of exhibition draws over 220,000 attendees
1,902 paid business buyers, an increase of 6.8% from last year
Improved conference and investment market satisfaction

(BUSINESS WIRE)-- Global Game Exhibition "G-STAR 2016" which was attended by 653 vendors (2,719 booths) from 35 countries around the world, recently ended with a great success achieving the best results ever in its history in both public and business areas.

"G-STAR 2016" organized by the Korea Internet Digital Entertainment Association (K-iDEA) and managed by the G-STAR Organizing Committee and the Busan IT Industry Promotion Agency was held at Busan, BEXCO for four days from November 17 (Thursday) until November 20 (Sunday).

This year marked the 12th "G-STAR" exhibition which showcased various entertainment exhibitions encompassing the exhibit space of approximately 55,300 square meters.

In particular, this year's "G-STAR 2016" was headed by a slogan of "Play To The Next Step" which presented many possibilities of forecasting the future of the game industry.

In addition, as a comprehensive game show that covers all platforms from online to mobile and to console, "G-STAR 2016" drew passionate responses from the visitors who visited the venue throughout the event period.

The Business Area located at exhibition centerⅡof BEXCO confirmed its position as the best game business exhibition in Asia. Particularly, paid trade visitors recorded 1,902 registrations which was an increase of 6.8% from 2015 which had 1,781 registrations, resulting in lively game business consultations.

Mr. Kwanho Choi, Chairman of G-STAR organizing Committee said, "With active participation by users who love to play games and game corporations, this year's 'G-STAR 2016' was able to produce positive results again," and added: "We, at 'G-STAR', will continue to work hard to develop various new contents and strive to maintain our status as a global game exhibition."

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

Photos/Multimedia Gallery Available:


G-STAR Secretariat

Jeonghun Kim, +82-2-6000-6694

General Manager


SES to Carry More HDTV Channels for M7 Group in Central Eastern Europe

New transponder leased by M7 will host all High Definition (HD) channels of the Czech public TV broadcaster, while the renewed capacity agreement will allow M7 to continue bringing HD quality to viewers in both the Czech Republic and Slovakia via Skylink

LUXEMBOURG - Tuesday, November 29th 2016 [ME NewsWire]

(BUSINESS WIRE)-- SES S.A. (Euronext Paris:SESG) (LuxX:SESG) announced today that the satellite television provider M7 Group has contracted additional capacity and extended an existing capacity contract on SES’s ASTRA 3B satellite positioned at 23.5 degrees East.

The new multi-year agreement will allow M7 Group to host all HD channels of the Czech public broadcaster Česká Televize, as well as new HD channels for Skylink, M7’s Direct-to-Home (DTH) television platform for the Czech Republic and Slovakia. The renewed capacity agreement will enable M7 to continue carrying a wide range of HD channels via Skylink, the market-leading satellite television platform in these countries, which reaches over two million homes.

“This recent agreement with SES will enable us to satisfy the existing and growing consumer demand for better picture quality and innovative new programs in the Czech Republic and Slovakia, as well as allow us to further reinforce our positions in these highly competitive markets,” said Hans Troelstra, Chief Executive Officer at M7 Group. “SES has been our reliable partner in delivering a quality TV experience to our viewers, and we are looking forward to continuing this fruitful relationship.”

“M7 Group has been a long-standing partner, and we are pleased that our collaboration continues to grow,” said Ferdinand Kayser, Chief Commercial Officer at SES. “M7 has a leading position in the high definition broadcasting segment of the Czech Republic and Slovakia, and we are happy to continue contributing to this success by providing our reliable satellite services.”

Follow us on:





SES Pictures are available under

SES White papers are available under

About SES

SES (Euronext Paris:SESG) (LuxX:SESG) is the world-leading satellite operator, with more than 50 geostationary satellites (GEO) and, through its subsidiary O3b Networks, 12 medium Earth orbit satellites (MEO). Focusing on value-added, end-to-end solutions in four key market verticals (Video, Enterprise, Mobility and Government), SES provides satellite communications services to broadcasters, content and internet service providers, and mobile and fixed network operators, as well as business and governmental organizations worldwide. SES's fleet includes the ASTRA satellite system, which has the largest Direct-to-Home (DTH) reach in Europe. Through its ownership of O3b Networks, SES significantly enhances existing data capabilities, and is the first satellite provider to deliver a differentiated and scalable GEO-MEO offering worldwide. Another SES subsidiary, MX1, is a leading media service provider and offers a full suite of innovative digital video and media services. Further information available at:

About M7 Group

M7 Group SA, based in Luxembourg, is one of Europe’s largest operators of satellite and IP-based TV platforms. M7 Group uses different brands in different countries: CanalDigitaal and in the Netherlands, TV Vlaanderen in Flanders and TéléSAT in French speaking Belgium, AustriaSat/HD Austria in Austria, Skylink for the Czech and Slovak markets and M7 Deutschland in Germany. All brands offer tailor made packages for clients adapted to the local culture and language in these countries. Today, M7 Group SA provides more than 3 million viewers with hundreds of satellite and IP-based radio and television services in digital and HD quality. Since 2011, M7 Group SA also provides broadband and telephony services to its customers in the Netherlands and Belgium. M7 Platform Services provides broadcasters with end-to-end distribution solutions for DTH, cable and IPTV reception. European private equity firm Astorg is the majority shareholder of the M7 Group. For further information, please visit



Markus Payer

Corporate Communications

Tel. +352 710 725 500


Monday, November 28, 2016

Toshiba Promotes Move to Hydrogen Economy with Construction of Integrated Hydrogen Application Center

--Using newly developed H2One™ solution for logistics facilities to promote hydrogen supply system business for fuel cell vehicles--

TOKYO - Monday, November 28th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Toshiba Corporation (TOKYO:6502) today broke ground on a new Hydrogen Application Center at its Fuchu Complex in western Tokyo. Scheduled to start operation in April 2017, the center will be built around a newly designed H2One™ hydrogen power system that will use renewable energy to produce hydrogen and supply it to fuel-cell powered forklifts operating in Fuchu Complex. Fuel cells can be quickly refueled and are available 24 hours a day, a clear advantage over batteries.

Mr. Hiroyuki Ota, Project Manager of Toshiba’s Energy Systems and Solutions Company noted: “The Hydrogen Application Center is a stepping stone to building a new business. We will utilize experience and know-how gained from the Hydrogen Application Center to develop and deliver a H2One™ for use in factories, warehouses, logistics facilities and airports. We want to make Fuchu Complex an environmental model factory for the realization of a carbon-free society where hydrogen energy is widely used.”

The system is controlled by Toshiba’s groundbreaking hydrogen energy management system, H2EMS™, which includes a new hydrogen demand prediction function that forecasts supply requirements for fuel cell vehicles, allowing space saving optimization of the area devoted to hydrogen storage.

Toshiba Energy Systems & Solutions Company continues to contribute to the global expansion of hydrogen energy solutions, and the transition to a low-carbon hydrogen economy.

About Toshiba

Toshiba Corporation, a Fortune Global 500 company, channels world-class capabilities in advanced electronic and electrical product and systems into three focus business fields: Energy that sustains everyday life, that is cleaner and safer; Infrastructure that sustains quality of life; and Storage that sustains the advanced information society. Guided by the principles of The Basic Commitment of the Toshiba Group, “Committed to People, Committed to the Future”, Toshiba promotes global operations and is contributing to the realization of a world where generations to come can live better lives.

Founded in Tokyo in 1875, today’s Toshiba is at the heart of a global network of 551 consolidated companies employing 188,000 people worldwide, with annual sales surpassing US$50 billion (as of March 31, 2016).

Photos/Multimedia Gallery Available:


Press Contact:

Toshiba Corporation

Yuu Takase, +81-3-3457-2100

PR & IR Division


BenQ Brings a New Era of Big-Screen Video Game Play with W1210ST Home Projector

Featuring Low Input Lag, Game modes, 100” at 1.5 meters short-throw technology

Dubai, United Arab Emirates - Wednesday, November 23rd 2016 [ME NewsWire]

BenQ, the internationally recognized innovator of digital lifestyle products and a worldwide leader in home projection technology, is taking video gaming to the next level today by transforming living rooms into totally immersive gaming zones. The W1210ST home projector brings the thrill of 100 inch big-screen console play into any room of the house. The industry’s lowest input lag ensures fast responsiveness for an ultra-smooth video gaming experience, while the elimination of distracting motion blur cranks up in-game realism. With outstanding colors, customized Game modes, cinema-quality sound, and short throw technology (100” at 1.5 meters), the W1210ST expands your gaming world and commits to make you feel like you’re really in the game!

Some of the key features include:

Welcome to a New Era of Big-Screen Gaming

When it comes to immersive gaming, bigger means better. BenQ W1210ST takes your gameplay to an all new level as it projects a 100-inch image to fill your field of view. Whether you’re playing on the Xbox One, PS4™ or Wii U™, gamers can count on the W1210ST to deliver bigger, smooth and detailed visuals that lock them into the excitement. Plus the mobility of W1210ST home projector, gamer can choose to play where they want, and when they want.

Game Modes to Experience Highly Responsive Ultra-smooth Gaming

The W1210ST is the world’s first home projector optimized for low input lag to create a smoother and more responsive video game experience free from distractions and delays. The W1210ST also boasts microsecond DMD response times to eliminate unwanted motion blur. Customized Game modes further enhance performance under different play conditions.

Unmatched Visual Performance

The W1210ST’s 6X RGBRGB color wheel and Full-HD ensures every scene is bathed in vibrant, natural tones and hues, enhancing the realism.

A Riveting Audio Experience

The W1210ST makes a truly immersive experience even more real by adding CinemaMaster Audio+, powered by MaxxAudio. Lasers blast, bones crunch, and tires squeal with the help of the projector’s 20-watt speaker housed in a resonant sound chamber.

Superior Short Throw Projection Adapt for Any Space

Any room can be converted into the ultimate gaming zone with W1210ST’s array of adaptable features. The short-throw projector achieves 100 inches of viewing area when placed just 1.5 meters from the projection surface, and the 1.2X zoom allows even greater positioning freedom. The intuitive user interface makes operation so easy that even novices can feel like audiovisual experts.

BenQ has taken video gaming to a new level with the W1210ST Full HD home projector, delivering the lowest input lag for players to enjoy unbeatable gaming fun without interruption. It’s more than a game. It’s like starring in your very own action adventure. Please visit for more information.

About BenQ Corporation

Founded on the corporate vision of “Bringing Enjoyment ‘N’ Quality to Life”, BenQ Corporation is a world-leading human technology and solutions provider aiming to elevate and enrich every aspect of consumers’ lives. To realize this vision, the company focuses on the aspects that matter most to people today – lifestyle, business, healthcare and education – with the hope of providing people with the means to live better, increase efficiency, feel healthier and enhance learning. Such means include a delightful broad portfolio of people-driven products and embedded technologies spanning digital projectors, monitors, interactive large-format displays, audio products, cloud consumer products, mobile communications and lifestyle lighting. Because it matters. 

About BenQ Group

The BenQ Group is a $22+ billion powerhouse comprised of nearly 20 independent companies operating in over 30 countries across numerous industries with a combined workforce of over 100,000 employees.  Each Group member is a recognized leader in its own field, contributing to the BenQ Group’s vast resources, broad R&D, and distinct strategic strengths.  By leveraging each company’s vertical specialization to create true scale across horizontal markets, the BenQ Group controls a highly efficient value chain with the unrivaled ability to deliver critical components and world-class solutions in the following industries: TFT-LCD, green energy, fine chemicals and advanced materials, lighting, IC design, precision components, system integration, branded business, and service.  The Group is committed to profitable and sustainable businesses that share its long-standing vision of Bringing Enjoyment ‘N’ Quality to Life.

The BenQ Group companies are:  BenQ Corporation, AU Optronics Corporation (world’s top manufacturer of large-size TFT-LCD panels), Qisda Corporation, Darfon Electronics Corporation, BenQ ESCO Corp., BenQ Materials Corp., BenQ Guru Corp., BenQ Medical Center, BenQ Medical Technology Corp., BenQ AB DentCare Corp., Daxin Materials Corp., Dazzo Technology Corp., Darwin Precisions Corp., Lextar Electronics Corp., LILY Medical Corp. and Raydium Semiconductor Corp..


Marissa Pinto      

Absolute Public Relations, Tel: +971 50 754 1420


NINLARO™ (ixazomib) Receives Conditional Approval from the European Commission to Treat Multiple Myeloma

− Approval Based on TOURMALINE-MM1 Study Results, Which Demonstrated Statistically Significant Six-Month Improvement in Progression-Free Survival −

CAMBRIDGE, Mass. & OSAKA, Japan - Monday, November 28th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission has granted conditional marketing authorization for NINLAROTM (ixazomib) capsules, indicated in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy. The decision to approve NINLARO as the first and only oral proteasome inhibitor to treat multiple myeloma follows a positive opinion by the European Medicines Agency (EMA) Committee for Medicinal Products (CHMP) for Human Use in September 2016.

“For myeloma patients living in Europe, the approval of NINLARO means we have a new and effective treatment option available when we relapse,” said Bob Munro, a patient with multiple myeloma from the United Kingdom. “I applaud the European Commission for recognising the additional benefit that NINLARO will bring to patients, who not only want treatment options that are effective and tolerable, but also appreciate the convenient option of taking an oral treatment. I strongly hope this will be made available by national health systems across Europe as soon as possible.”

The European Commission followed the CHMP’s recommendation to approve NINLARO based on data from the pivotal Phase 3 TOURMALINE-MM1 trial, which demonstrated that NINLARO plus lenalidomide and dexamethasone increased the length of progression-free survival by about six months, or 40 percent, in patients with relapsed and refractory multiple myeloma when compared with placebo, lenalidomide and dexamethasone. The study also showed that the progression-free survival benefit observed in the NINLARO regimen extended across pre-specified subgroups of patients. Follow-up analyses for overall survival are planned for 2017.

“With the approval of NINLARO by the European Commission, physicians across the region will have the option to prescribe an all-oral triplet regimen to treat patients with multiple myeloma who have received at least one prior therapy,” said Philippe Moreau, MD, Head of the Hematology Department at the University Hospital of Nantes, France. “In the TOURMALINE-MM1 study, we saw a clinically meaningful six-month improvement in progression-free survival with NINLARO, evidence that has supported its approval in Europe. As a hematologist, I welcome the availability of this treatment to address a devastating disease like multiple myeloma.”

“When developing NINLARO, Takeda Oncology’s scientists sought to formulate an efficacious and unique oral proteasome inhibitor with a manageable safety profile. NINLARO delivers the proven efficacy of a proteasome inhibitor in a convenient once-weekly pill that can be taken at home,” said Christophe Bianchi, M.D., President, Takeda Oncology. “NINLARO has the potential to help European patients with relapsed multiple myeloma by removing some of the barriers that can stand in the way of optimal treatment. With NINLARO, our hope is that many patients will be able to continue therapy until disease progression. Following the European Commission’s approval, we will continue to study NINLARO in a variety of settings in the hopes that we can bring this medicine to as many of the patients who may benefit from it as possible.”

As a result of the European Commission decision, NINLARO is now approved for use across the European Economic Area, which includes the European Union’s 28 member states as well as Norway, Liechtenstein and Iceland. In addition, NINLARO is licensed for use in the U.S., Canada, Israel, Australia and Venezuela, and Takeda has submitted marketing authorization applications for NINLARO to a number of additional regulatory authorities around the world.

About NINLAROTM (ixazomib) capsules

NINLAROTM (ixazomib) is an oral proteasome inhibitor which is also being studied across the continuum of multiple myeloma treatment settings as well as systemic light-chain (AL) amyloidosis. It was the first oral proteasome inhibitor to enter Phase 3 clinical trials and to receive approval. NINLARO was approved by the U.S. Food and Drug Administration (FDA) in November 2015 following a priority review. In the U.S., NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Ixazomib was granted orphan drug designation in multiple myeloma in both the U.S. and Europe in 2011 and for AL amyloidosis in both the U.S. and Europe in 2012. Ixazomib received Breakthrough Therapy status by the U.S. FDA for relapsed or refractory systemic light-chain (AL) amyloidosis in 2014.

The comprehensive ixazomib clinical development program, TOURMALINE, further reinforces Takeda’s ongoing commitment to developing innovative therapies for people living with multiple myeloma worldwide and the healthcare professionals who treat them. TOURMALINE includes a total of five ongoing pivotal trials – four, which together are investigating every major multiple myeloma patient population, and one in light-chain amyloidosis:

    TOURMALINE-MM1, investigating ixazomib vs. placebo, in combination with lenalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    TOURMALINE-MM2, investigating ixazomib vs. placebo, in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
    TOURMALINE-MM3, investigating ixazomib vs. placebo as maintenance therapy in patients with newly diagnosed multiple myeloma following induction therapy and autologous stem cell transplant (ASCT)
    TOURMALINE-MM4, investigating ixazomib vs. placebo as maintenance therapy in patients with newly diagnosed multiple myeloma who have not undergone ASCT; this study is currently enrolling
    TOURMALINE-AL1, investigating ixazomib plus dexamethasone vs. physician choice of selected regimens in patients with relapsed or refractory AL amyloidosis; this study is currently enrolling

In addition to the TOURMALINE program, ixazomib is being evaluated in multiple therapeutic combinations for various patient populations in investigator initiated studies globally.

NINLAROTM (ixazomib): Global Important Safety Information


Thrombocytopenia has been reported with NINLARO (28% vs. 14% in the NINLARO and placebo regimens, respectively) with platelet nadirs typically occurring between Days 14-21 of each 28-day cycle and recovery to baseline by the start of the next cycle. It did not result in an increase in hemorrhagic events or platelet transfusions. Monitor platelet counts at least monthly during treatment with NINLARO and consider more frequent monitoring during the first three cycles. Manage with dose modifications and platelet transfusions as per standard medical guidelines.

Gastrointestinal toxicities have been reported in the NINLARO and placebo regimens respectively, such as diarrhea (42% vs. 36%), constipation (34% vs. 25%), nausea (26% vs. 21%), and vomiting (22% vs. 11%), occasionally requiring use of antiemetic and anti-diarrheal medications, and supportive care.

Peripheral neuropathy was reported with NINLARO (28% vs. 21% in the NINLARO and placebo regimens, respectively). The most commonly reported reaction was peripheral sensory neuropathy (19% and 14% in the NINLARO and placebo regimens, respectively). Peripheral motor neuropathy was not commonly reported in either regimen (< 1%). Monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed.

Peripheral edema was reported with NINLARO (25% vs. 18% in the NINLARO and placebo regimens, respectively). Evaluate patients for underlying causes and provide supportive care, as necessary. Adjust the dose of dexamethasone per its prescribing information or the dose of NINLARO for severe symptoms.

Cutaneous reactions occurred in 19% of patients in the NINLARO regimen compared to 11% of patients in the placebo regimen. The most common type of rash reported in both regimens was maculo-papular and macular rash. Manage rash with supportive care, dose modification or discontinuation.

Hepatotoxicity, drug-induced liver injury, hepatocellular injury, hepatic steatosis, and hepatitis cholestatic have been uncommonly reported with NINLARO. Monitor hepatic enzymes regularly and adjust dose for Grade 3 or 4 symptoms.

Pregnancy- NINLARO can cause fetal harm. Advise male and females patients of reproductive potential to use contraceptive measures during treatment and for an additional 90 days after the final dose of NINLARO. Women of childbearing potential should avoid becoming pregnant while taking NINLARO due to potential hazard to the fetus. Women using hormonal contraceptives should use an additional barrier method of contraception.

Lactation- It is not known whether NINLARO or its metabolites are excreted in human milk. There could be potential adverse events in nursing infants and therefore breastfeeding should be discontinued.


Hepatic Impairment: Reduce the NINLARO starting dose to 3 mg in patients with moderate or severe hepatic impairment.

Renal Impairment: Reduce the NINLARO starting dose to 3 mg in patients with severe renal impairment or end-stage renal disease (ESRD) requiring dialysis. NINLARO is not dialyzable and, therefore, can be administered without regard to the timing of dialysis.


Co-administration of strong CYP3A inducers with NINLARO is not recommended.


The most frequently reported adverse reactions (≥ 20%) in the NINLARO regimen, and greater than in the placebo regimen, were diarrhea (42% vs. 36%), constipation (34% vs. 25%), thrombocytopenia (28% vs. 14%), peripheral neuropathy (28% vs. 21%), nausea (26% vs. 21%), peripheral edema (25% vs. 18%), vomiting (22% vs. 11%), and back pain (21% vs. 16%). Serious adverse reactions reported in ≥ 2% of patients included thrombocytopenia (2%) and diarrhea (2%). For each adverse reaction, one or more of the three drugs was discontinued in ≤ 1% of patients in the NINLARO regimen.

For US Prescribing Information:

For Canada Product Monograph:

About Multiple Myeloma

Multiple myeloma is a cancer of the plasma cells, which are found in the bone marrow. In multiple myeloma, a group of monoclonal plasma cells, or myeloma cells, becomes cancerous and multiplies. These malignant plasma cells have the potential to affect many bones in the body, possibly resulting in compression fractures, lytic bone lesions and related pain. Multiple myeloma can cause a number of serious health problems affecting the bones, immune system, kidneys and red blood cell count, with some of the more common symptoms including bone pain and fatigue, a symptom of anemia. Multiple myeloma is a rare form of cancer, with approximately 39,000 new cases in the EU and 114,000 new cases globally per year.

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit

Additional information about Takeda is available through its corporate website,, and additional information about Takeda Oncology, the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited, is available through its website,

To view NINLARO (ixazomib) Fact Sheet, please click here

To view Multiple Myeloma Infographic, please click here

To view Multiple Myeloma Fact Sheet, please click here

To view NINLARO (ixazomib) Mechanism of Action​, please click here

To view TOURMALINE Fact Sheet​​, please click here

This Smart News Release features an interactive multimedia capsule. View the full release here:


Takeda Pharmaceutical Company Limited

European Media

Kate Burd, +41 79 514 9533


Japanese Media

Tsuyoshi Tada, +81 (0) 3-3278-2417


Media outside Japan/EU

Amy Atwood, +1-617-444-2147


Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss

INGELHEIM, Germany & NANJING, China - Monday, November 28th 2016 [ME NewsWire]

    360 million people worldwide suffer from disabling hearing loss with no effective treatment available
    New collaboration with China Southeast University is part of the Research Beyond Borders (RBB) initiative, which aims to explore emerging science within and beyond Boehringer Ingelheim’s therapy areas of focus
    The new project underscores Boehringer Ingelheim’s commitment to bring medical breakthroughs to patients in need by investing in early research and ground-breaking science

(BUSINESS WIRE)-- Boehringer Ingelheim and China Southeast University Institute of Life Sciences today announced the start of a joint research project to develop new treatment approaches for hearing loss through regeneration of hair cells from inner ear stem cells. The new collaboration combines the expertise of Professor Renjie Chai, one of the worldwide leaders in the field of hearing loss, with Boehringer Ingelheim’s expertise in drug discovery and clinical development to pave the way for the development of much needed new treatment options for this condition.

According to WHO data, over 360 million people live with disabling hearing loss, of which 32 million are children under15 years old. The prevalence of hearing loss increases with age and has a serious impact on the elderly by diminishing their ability to communicate and affecting their daily quality of life. A dramatic increase in frequency of the condition is predicted as a result of worldwide aging populations. Patients with hearing loss usually have degeneration of inner ear hair cells. There is no effective treatment that could restore hearing loss.

“Professor Renjie Chai and his team are among the world leaders in this emerging research area. We are excited about initiating this collaboration, which is an important next step towards a new focus area for our research and development and our first human pharma research collaboration in China,” said Clive R. Wood, Ph.D., Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This is our second collaboration in hearing loss, one of the focus areas of our Research Beyond Borders initiative. It is an outstanding example of how this unique initiative will boost our R&D by partnering with the most innovative scientists working at the forefront of biomedical research.”

The new research collaboration in hearing loss is an initiative of Boehringer Ingelheim’s newly established organisation Research Beyond Borders (RBB). It complements a research collaboration with Kyoto University initiated earlier this year that focuses on utilising findings on hair cell regeneration in birds. Through the collaboration with China Southeast University, Boehringer Ingelheim will investigate key signaling pathways and proteins involved in regeneration in the inner ear to develop a drug discovery strategy to target hair cell regeneration and ultimately address the unmet medical need in hearing loss via regenerative medicine approaches.

Dr. Wei Xie, Dean of China Southeast University Institute of Life Sciences commented: “Through this joint project with Boehringer Ingelheim, a world leading innovative pharmaceutical company, we wish to further promote scientific development in the field of hair cell regeneration, and to accelerate the translation of basic science to clinical applications. The current collaboration will demonstrate the regulation mechanism of inner ear stem cells, and we hope to develop insights for targeting the key pathways via small molecule compounds together with Boehringer Ingelheim.”

RBB is one of the pillars of Boehringer Ingelheim’s R&D strategy. It complements the company’s five core therapeutic areas (cardiometabolic, respiratory and central nervous system diseases, immunology and oncology) by exploring emerging science, disease areas and technology. It will contribute new innovation opportunities within and beyond the core therapeutic areas and ensure early entry for Boehringer Ingelheim in the next big innovation waves in in biomedical research. RBB is currently focusing on the areas of regenerative medicine, the microbiome and new technologies such as gene therapy.

Asia is rapidly becoming an innovation a hot spot in biomedical research and has gained a leading position in regenerative medicine research. Boehringer Ingelheim is thus expanding its activities in this region and looking for more partnering opportunities. By combining a focus on cutting-edge science with a long-term view the company aspires to develop the next generation of medical breakthroughs to improve the lives of patients with high unmet medical needs.

For ‘Notes to Editors’ please visit:


Boehringer Ingelheim

Dr. Reinhard Malin

Director Corporate Communications

Tel. +49 (6132) 77-90815


The 7th China Maritime to Be Held in March 2017 in Beijing

BEIJING - Monday, November 28th 2016 [ME NewsWire]

(BUSINESS WIRE)-- As China’s leading maritime exhibition, China Maritime – The 7th International Offshore Engineering Technology & Equipment Exhibition (CM) will be held on March 20-22, 2017 at New China International Exhibition Center in Beijing, concurrently with the 17th China International Petroleum & Petrochemical Technology and Equipment Exhibition (cippe2017).

In recent years, the Chinese government is increasing support for maritime exhibitions especially after Chinese President Xi Jinping proposed the “One Belt, One Road” Initiative, which was echoed later by Chinese Premier Li Keqiang, who called on the construction of a maritime silk road linking China and the ASEAN countries to stimulate hinterland development.

Leveraging the global vision of Beijing, China Maritime aims to promote global cooperation on maritime technologies & equipment and help enterprises generate social benefits and build itself into a high-end exhibition in the maritime industry. China Maritime, with an exhibition area of 100,000m2, attracted a total of 100,000 visitors and 2,000 exhibitors from around 65 countries and regions, among which 46 were Fortune 500 enterprises.

Maritime industry has gained strong support from Chinese government

China is strengthening its efforts to develop the maritime industry. For the next five years, the global demand for maritime engineering equipment is estimated to be worth $60-75 billion, and China is going to invest RMB 250-300 billion or $36.9-44.2 billion in maritime engineering equipment manufacturing during the 13th Five-Year Plan (2016-2020).

Chinese market performs well as global offshore engineering market stays sluggish

The newbuilding order size experienced a sharp decline globally in the second half of 2016. Nevertheless, the Chinese market performed well with its newbuilding market share rising to 50.5% from 47.9% in 2013, defending its world’s first place. Meanwhile, it signed orders for 31 sets of offshore engineering equipment and 149 offshore engineering vessels, worth a total of $14.76 billion and accounting for 35.2% of the global market.

China Maritime is a high-end arena for global offshore engineering giants

China Maritime 2016 attracted a large number of prestigious enterprises and organizations including Det Norske Veritas, Panama Maritime Authority, Rosneft, Baker Hughes, National Oilwell Varco, GE, Cameron, Schneider, Honeywell, API, Caterpillar, Cummins, MTU, Tyco, Atlas, Aker Solution, Jotun Paints, HEMPEL, PANASIA, Siemens and ABB, as well as China State Shipbuilding Corporation, China National Offshore Oil Corporation, China National Petroleum Corporation, Sinopec, etc. and nearly 1,000 media outlets around the world reported the event.

In addition, last year’s event also attracted around 100 buyer delegations to negotiate business on site, including delegations from Ulstein, Bourbon, McDermott, Icon Offshore, POSH Semco, Bhagwan Marine, and China’s COSCO, COSL, Sinotrans & CSC Holdings etc.


Organizing Committee of cippe 2017

General Inquiry

Mandy, +86-10-59273880


Media Enquiry

Linda Liang, +86-10-58236579 / 18701599799


Sunday, November 27, 2016

Tata Motors targets 12,000 customers through unique customer outreach program, covering 47 countries and 800 touchpoints

 Launches three-day Global Service Camp, starting November 21

MUMBAI, India - Tuesday, November 22nd 2016 [ME NewsWire]

(BUSINESS WIRE)-- In continuation with Tata Motors customer-centric thrust towards best customer experience of its commercial vehicle range, the company today announced its three-day Global Service Camp from 21st to 23rd November 2016. The unique customer outreach program will cover 800 touch points in 47 countries.

Tata Motors commercial vehicle customers can avail free comprehensive vehicle health check-ups, free labor (through the warranty system), special schemes on lubes by TOTAL, along with various value added services. During the three-day service campaign, Tata Motors will also offer attractive discounts on Tata Genuine Spares and reward driver owners, reporting with their vehicle to the service campaign, with exciting gifts. The campaign will also include ‘High Mileage’ Awards for drivers.

Additionally, during the three-day service camp Tata Motors will also offer special pricing on its range of commercial vehicles, where customers can make inquiries, test-drive and experience some of Tata Motors new products and services. The service campaign will also involve various training initiatives for drivers cum operators, introducing and briefing them on new commercial vehicle technologies related to safety and vehicle productivity. Videos on safe vehicle operation and performance, will also be played at customer lounges across Tata Motors dealerships.

Mr. Ganesh Shetty, Head – Customer Care (International Business) Commercial Vehicles, Tata Motors Ltd., said, “Tata Motors’ vehicles are recognized for their reliability and efficiency and through our Global Service Campaign, we hope to further reinforce that message, by inviting our customers for a comprehensive vehicle check, for the best vehicle performance. Through the Global Service Camp, we will not only help address the servicing needs of our customers’ vehicles, but will also take this opportunity to further access their needs, to better our product and service offerings going forward. Through this global campaign, we aim to target more than 12,000 customers globally.”

Tata Motors is among the Top 10 truck and bus manufacturers globally, with the most extensive range of commercial vehicles arising from day-to-day needs. With vast global experience, the company brings a deep understanding of customer expectations from diverse markets and is well positioned to cater to ever changing automotive norms and commercial vehicle trends across the globe. Tata Motors continues to invest in its products, its sales & service network, with an aggressive customer centric approach of anticipating customer requirements.

About Tata Motors:

Tata Motors Limited is India’s largest automobile company, with consolidated revenues of INR 2,75,561 crores (USD 41.6 billion) in 2015-16. Through subsidiaries and associate companies, Tata Motors has operations in the UK, South Korea, Thailand, South Africa and Indonesia. Among them is Jaguar Land Rover, the business comprising the two iconic British brands. It also has an industrial joint venture with Fiat in India. With over 9 million Tata vehicles plying in India, Tata Motors is the country’s market leader in commercial vehicles and among the top in passenger vehicles. Tata cars, buses and trucks are being marketed in several countries in Europe, Africa, the Middle East, South Asia, South East Asia, South America, Australia, CIS and Russia.

(; also follow us on Twitter:    


Tata Motors Corporate Communications

Arthur Serrao


Tel: +91 22-66657613


Saturday, November 26, 2016

Korea Racing Authority to Host Contest for 'Space Design and Operation Plan of Land'

SEOUL, South Korea - Wednesday, November 23rd 2016 [ME NewsWire]

(BUSINESS WIRE)-- Korea Racing Authority (Chairman: Myung-Kwan Hyun) announced that it will host a contest for ‘Space Design and Operation Plan of Land’ in Seocho-dong, Seoul, starting on November 16, 2016 to January 17, 2017.

The contest is designed to plan the ‘space with a new brand’ by transforming current business programs and realizing innovation, exploration of future business areas and value of social contribution, using its own land.

The projected land is an estate of Korea Racing Authority in space of 1,400.4 square meters located near the subway station in Seocho-dong Seocho-gu, Seoul. It provides convenient transportation and it has strong effect of gathering people with a large floating population as it is neighboring to business facilities, a university and residential areas.

The underlying principle in preparing a proposal for the contest is ‘Brandscaping.’ Ahead of the 100th anniversary of introducing horse race that marks in 2022, the proposal should be creatively designed in the way of removing negative image of speculation business of Korea Racing Authority and realizing innovation, exploration of future business areas and value of social contribution. And it also should include state-of-the-art facilities that comprise future business areas and horse-related contents, which can serve as experiencing or entertaining space with easy and convenient accessibility.

“We plan to enhance the value of corporate brand by building a space that will help Korea Racing Authority and horse-related industry contribute to better life of Korean people by exploring innovative ideas that can lead the future rather than using already developed contents,” said Myung-Kwan Hyun, Chairman of Korea Racing Authority. “We hope a large number of specialists around the world will actively take part in the contest of Space Design and Operation Plan of Land in Seocho-dong, Seoul.”

The winner of the best prize will be granted with a right to design, produce and install the content proposed by him or her within the budget of up to 10.6 billion won (approx. 9.1 million dollars). Four other prize winners will be granted with a total of 120 million won combined.

For further inquiry on the contest, please send e-mail to or visit (, Biz-News).


Media Contact

Korea Racing Authority

Oh Mong-ho, 82-2-6006-3623/3621

Asset Innovation Team


CING2017 and CIPE2017 to Kick off Concurrently With cippe2017, Aiming to Boost Cooperation on Gas Technology and Equipment

BEIJING - Monday, November 21st 2016 [ME NewsWire]

(BUSINESS WIRE)-- The 7thChina International Natural Gas Technology and Equipment Exhibition (CING2017) and the 17th China International Exhibition on Equipment of Pipeline, and Oil & Gas Storage and Transportation (CIPE2017, Asia’s largest natural gas pipeline exhibition), will be held concurrently with the 17th China International Petroleum & Petrochemical Technology and Equipment Exhibition (cippe2017) at the New China International Exhibition Center in Beijing on March 20-22, 2017. With an exhibition area of 100,000m2 and featuring 18 international pavilions, the events are expected to gather 2,000 exhibitors, including 46 Fortune 500 companies, from 65 countries and regions, and attract 80,000 visitors.

Exhibitors of previous events include major Chinese companies like CNPC, Sinopec, CNOOC, Jereh and foreign companies like, Gazprom, ExxonMobil, Schlumberger, and Cater Pillar. While major international players like Total, Shell, BP, and Qatar Petroleum are frequent visitors to the event.

In recent years, the determination of governments worldwide to cut down PM2.5 index has already pressed many industries to abandon coal as a major energy source. In addition, the validation of the Paris Agreement on November 4 this year will surely accelerate the global shift to clean energy, of which gas will account for a dominant proportion.

Zhao Yujian, Head of China Petroleum Pipeline Bureau, commented, “The construction of storage and transmission facilities in oil & gas-rich regions such as Middle East, Central Asia and Russia is under stable growth. Meanwhile, China is advancing its ‘One Belt and One Road’ Initiative as well as multiple other projects such as the Asian Infrastructure Investment Bank, the Silk Road Fund, and the China-Africa Development Fund, which will all bring historical opportunities for international pipeline development. With China speeding up its pace for a moderately prosperous society, the demand for oil and gas, especially natural gas and LNG, will remain strong, generating enormous development potential for oil & gas pipeline and storage equipment.”

China’s gas consumption will reach 360-400 billion cubic meters by 2020 and increase to 500 billion cubic meters by 2030. Experts estimate that by the end of the 13th Five-Year Plan (2016-2020), China’s long-distance oil & gas transmission pipelines mileage will surpass 160,000km.

Currently, many cross-border pipeline projects are under construction. The 4,000km China-Russia East Route natural gas pipeline, starting from Eastern Siberia and running through China’s 9 provinces, is planned to complete in 2018. The China-Kyrghyzstan gas pipeline, planned to reach 215km, is being constructed as part of the China-Central Asia gas pipeline network.

CING and CIPE will ally with the world’s largest oil exhibition cippe to provide a comprehensive platform for exhibitors and professional buyers from enterprises, government, research institutes and industry associations for business cooperation and gas technology exchange.

For more information, please visit:




Organizing Committee of cippe 2017

General Inquiry

Maci, +86-10-58236588/6555


Media Enquiry

Linda Liang, +86-10-58236579/18701599799


Thursday, November 24, 2016

OT Provides a Unified Transportation Payment Card in the Philippines

COLOMBES, France - Thursday, November 24th 2016 [ME NewsWire]

(BUSINESS WIRE)-- OT (Oberthur Technologies), a leading global provider of embedded security software products, services and solutions, today announced its partnership with AF Payments Inc. (AFPI) to provide multi-purpose smart cards in the Philippines to allow end-users to have one single card to commute and pay in Manila.

There are a lot of unbanked people in The Philippines. In order to allow them to easily use transportation in Manila and in the same way be able to pay, AFPI decided to offer them a single card. To do so, OT provides the multi-purpose smart cards enabling commuters to connect from one train line to another without the hassle of changing tickets. The card can also be used in select bus lines and toll ways. In addition to transportation, cardholders will soon be able to pay for goods via a stored value account loaded in the smart card.

“We are privileged to be the certified partner of AFPI and to support them in offering a multi-purpose card to Filipinos that will enable to have one single card to transit and pay for goods. This will also help in the development of urban transport in Manila. OT has demonstrated its expertise in transportation and payment markets worldwide, so we were able to meet stringent technical requirements from AFPI” said Mark Garvie, Asia Financial Services Institutions Managing Director at OT.

“OT has a strong local presence and excellent reputation in the Philippines so they are an ideal partner to provide a smart card which enables end-users to commute easily and pay securely. We have our hearts set on offering payment means to the unbanked segment and offering a payment service via a stored value smart card is the best solution. AFPI is extending this functionality to banks and other financial institutions to make the “beep” cards accessible to all Filipinos” said Peter Maher, President and CEO at AFPI.


OT is a world leader in embedded digital security that protects you when you connect, authenticate or pay.

OT is strategically positioned in high growth markets and offers embedded security software solutions for “end-point” devices as well as associated remote management solutions to a huge portfolio of international clients, including banks and financial institutions, mobile operators and governments, as well as manufacturers of connected objects and equipment.

OT employs over 6,500 employees worldwide, including almost 700 R&D people. With a global footprint of 4 regional secure manufacturing hubs and 39 secure service centers, OT’s international network serves clients in 169 countries. For more information:


Download The M World,
All you need to know about the latest trends of the Mobility world, available on AppStore and Google Play




Chloé Tisseuil, Tél. : +33 1 86 21 50 54


TRUSTECH 2016, The Most Innovative Companies of the Trust-Based Technology Industry Meet in Cannes

PARIS - Thursday, November 24th 2016 [ME NewsWire]

(BUSINESS WIRE)-- SESAMES Awards, focusing on innovation

Each year at TRUSTECH, the SESAMES Awards are given to the best innovations in the fields of payments, identification, digital security and wireless technologies.

18 exhibiting companies have been selected as finalists by a jury made up of 18 international experts. The selection was based on three fundamental criteria: the innovative characteristics of the product/service submitted, the market suitability and the strength of the pitch.

It's on the Main Stage of TRUSTECH that the 6 SESAMES winners will be rewarded on 29 November in the categories of e-transaction, retail and manufacturing; then on 30 November in the categories of IoT, e-government and cyber security.

The 18 finalists of the SESAMES awards


Name of project


Passwordless Remote Authentication
BioSSL ltd (UK)          

Spire Payments (UK)          

Spire Mobile Framework

Fido BLE Card
Vision Box (PO)          

Happy Flow Smart Cities

The Nautilus
MeReal Biometrics (HK)          

MeReal Biometrics

FAMOCO, by World Food Programme & FAMOCO (FR)

SCOPECARD, a digital solution for humanitarian food assistance
TableSafe (USA)          

TableSafe RAIL pay-at-the-table payment platform
KEOLABS (FR)          


          RFID / NFC Anti-Counterfeit Solution    

SMARTRAC dLoc System
COMPRION GmbH (DEU)          

COMPRION Network Bridge

Manufacturing and
COMPRION GmbH (DEU)          

SPS (FR)          

Innovative Dual interface "Heavy Metal" card
VirtuCrypt (USA)          

VirtuCrypt Elements - Remote Key Loading Service
TableSafe (USA)          

TableSafe RAIL pay-at-the-table payment platform

TAS Group (IT)


Major players and start-ups brought together by innovation

The Main Stage of TRUSTECH will also be dedicated to the 40 start-ups in the Fintech, IoT, payments and digital identity sectors, invited to participate in the pitch sessions.
The exhibitors and sponsors will also present their latest products and services on the Main Stage.

Focus on a few highlights

Connected objects
Wetech has developed a range of connected accessories and jewellery (watches, bracelets, rings, necklaces, etc.), using wireless technology to be used as POS. The company has also created apps paired to their wearables, in order to control and secure them.

Companies such as TAS Group is helping to bring down barriers which exist in the field of cross-border payments by simplifying the validation and processing of this type of operation by taking into account the local regulations and commercial practices. As for Snapswap, the company combines mobile messenger app functions (such as Facebook Messenger and WhatsApp) with digital wallet and peer-to-peer transactions (such as PayPal) into a single app called Gloneta.

Another field where innovation is particularly impressive is biometrics; companies such as Flexenable and Innovatrics both integrate digital fingerprint readers on smart cards in order to increase security and broaden their functionalities.

Point of sale terminals
The main stakeholders on this market, such as Spire Payments, XAC Automation and Verifone with " Carbon" will present the latest generation of point of sale terminals. These latest products now include advanced functionalities, access to the cloud and the availability of various apps.

More information and registration at

About TRUSTECH (Incorporating Cartes): Created over 30 years ago under the name CARTES SECURE CONNEXIONS to promote the new-born technology of smart cards, it has been re-named TRUSTECH (incorporating CARTES), to better reflect the way the industry and the event have evolved, and its focus on trust-based technologies.

About COMEXPOSIUM: The COMEXPOSIUM Group, one of the world’s leading event organizers, is involved in more than 170 B2C and B2B events across 11 different sectors, including food, agriculture, fashion, security, digital technologies, construction, high tech, optics and transport. COMEXPOSIUM hosts more than 3 million visitors and 45,000 exhibitors in 26 countries around the world. COMEXPOSIUM operates globally with a presence in over 30 countries.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

View source version on



Press contact: Vianova agency

Sandra Codognotto, 01 53 32 28 58


Lisa Dubreuil, 01 53 32 28 37


Retail Banking Growth in Emerging Markets Slows According to New Oliver Wyman Report

NEW YORK - Thursday, November 24th 2016 [ME NewsWire]
(BUSINESS WIRE)-- Retail bank growth across 12 emerging markets, referred to as the EM12, will slow according to a new report titled “Playing to Win, Retail Banking Strategies for Emerging Markets” from Oliver Wyman.
“The nature of retail banking growth in EM12 is undergoing a major change,” said Oliver Wyman partner Michael Wagner. “With slower growth rates, banks need long-term, cohesive strategies, which will allow them to grow faster and create clear separation between winners and laggards.”
The EM12 include China, Indonesia, Malaysia, Thailand, India, Saudi Arabia, Turkey, South Africa, Brazil, Mexico, Chile and Colombia. These markets saw rapid growth – an average of 18 percent a year – between 2010 and 2013. Growth was fueled by rises in household income and strong macroeconomic conditions, among other factors. These markets accounted for more than 75 percent of global financial services revenue growth between 2010 and 2013 according to the report.
However, there has been a significant slowdown across a number of major markets over the past two years, due primarily to slowing GDP growth, increasing volatility in currency markets, and changing credit cycles. The report predicts slower growth will continue over the next five years, with overall retail revenue growth in the EM12 falling to nine percent between 2015 and 2020. Declines in growth will be most pronounced in China, Brazil, Mexico, Thailand and Saudi Arabia.
In spite of the relative slowdown, EM12 will continue to be the driver of global growth in retail banking because the top ten developed markets are expected to grow by only two percent annually over the next five years. Over this period, the EM12 retail banking revenue will grow by more than US$450 billion. This will be fueled by the extension of access to financial services to an additional 250 million households and the increasing need for financial services from another 90 million households as they transition from the mass market to the mass affluent segment.
The report identifies four key opportunities which will define outperformance for EM12 banks:
1. Adoption of digital channels, products and business models
2. Untapped opportunity in small and medium-sized enterprises (SMEs)
3. Sustainable growth in retail credit
4. Development of an affordable banking proposition
“Despite the slower growth across the region, there is still a great opportunity for the EM12 compared to developed markets, since there is more room for expansion and business models remain more profitable,” Wagner added. “Effective response will lead to accelerated growth in performance, enabling market leaders to grow as much as two to four times as fast as lagging institutions.”
About Oliver Wyman
With offices in 50+ cities across 26 countries, Oliver Wyman is a global leader in management consulting that combines deep industry knowledge with specialized expertise in strategy, operations, risk management, and organization transformation. Oliver Wyman is a wholly owned subsidiary of Marsh & McLennan Companies [NYSE: MMC]. For more information on Oliver Wyman visit Follow Oliver Wyman on Twitter @OliverWyman.    


For Oliver Wyman
Francine Minadeo, 212-345-6417


Gilat Satcom Connects DRC Customers Over Reliable, High Performance O3b Network

Service Provider now offering fiber-equivalent satellite connectivity for customers coping with uneven terrestrial fiber connection in capital city

ST. HELIER, Jersey, Channel Islands - Wednesday, November 23rd 2016 [ME NewsWire]

(BUSINESS WIRE)-- O3b Networks and Gilat Satcom have announced that Gilat Satcom has gone live on O3b’s unique ‘Fiber in the Sky’ satellite network, offering latency and throughput comparable to fiber over the O3b satellite-enabled global network.

A member of the Eurocom Group and winner of best satellite service for 2016 in Capacity Africa, Gilat Satcom offers satellite and fiber-based connectivity solutions in Africa, Asia and the Middle East. The company operates three international teleports in Europe and the Middle East, multiple hubs/PoPs in Africa, Europe and the US. Gilat Satcom is currently delivering vital connectivity across the Democratic Republic of Congo (DRC), including to the capital city of Kinshasa.

Although DRC is connected by terrestrial fiber cables, the country’s population of 80 million experiences occasional challenges with connectivity over the land-based link. O3b was chosen by Gilat Satcom because it is the only satellite network comparable to the performance of fiber both in latency and throughput, while providing superior reliability for voice, video and other data services Gilat Satcom’s customers rely upon.

For Gilat Satcom’s mobile network operator (MNO) and internet service provider (ISP) customers, the improved reliability of O3b’s fiber-in-the-sky solution will make an enormous difference. The O3b link enables high-speed broadband internet access, mobile LTE and 3G data traffic, and is used to backup and compliment the fiber infrastructure. The O3b solution provides superior reliability through both route and site diversity, resulting in a high availability, high performance service.

“We are investing heavily in both our fiber and satellite operations throughout Africa. Our customers need reliable connectivity to make their businesses work, so the redundant high-performance connection O3b provides is essential,” said Ofer Doron, Gilat’s VP Engineering. “Having diverse routing options beyond just fiber provides the vital network stability our customers demand.”

“We are very excited to be working with Gilat, bringing the people of DRC the internet performance over satellite they would normally expect over fiber,” said Carole Kamaitha, VP Africa for O3b Networks. “O3b’s network provides even remote, land-locked locations all the internet capabilities they need, enabling online education, telemedicine and e-government services.”

Additional Resources

    Visit the O3b Blog
    Follow O3b on LinkedIn
    Like O3b on Facebook
    Follow O3b on Twitter

About O3b Networks Limited

O3b Networks Ltd. is a provider of global managed communication services and operates both a state-of-the-art fleet of high throughput, low latency satellites and a global terrestrial infrastructure. O3b delivers carrier-grade Data Networking Solutions to ISPs, telcos, mobile network operators, governments and enterprises in the most remote and inaccessible places on the planet. O3b Networks is a wholly owned subsidiary of SES (Euronext Paris and Luxembourg Stock Exchange: SESG).

About Gilat Satcom

Gilat Satcom is a communication solutions provider that offers satellite and fibre-based connectivity solutions in Africa, Asia and the Middle East.

With successful deployments in 50 countries, Gilat Satcom consistently delivers high-quality, cost-effective and efficient communications solutions to telcos, ISPs, governments, enterprise customers and international organizations. 

The company operates three international teleports in Europe and the Middle East, multiple hubs/PoPs in Africa, Europe and the US. In addition, Gilat Satcom is a shareholder in WIOCC, owners of the East African Submarine System (EASSy), and in the West Africa Cable System (WACS), with undersea fibre-optic cable systems connecting eastern and western Africa to the rest of the world. Gilat Satcom also provides space segments over numerous satellites including Intelsat, Telesat, Hellas Sat, ABS, SES-NewSkies and others.

For more information please visit


O3b Networks

Jason Wauer


SpeakerBox Communications for O3b

Kate Nesbitt, +1 703 287 7814